KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Accumulated Expenses (2016 - 2025)

BeOne Medicines (ONC) has disclosed Accumulated Expenses for 11 consecutive years, with $1.0 billion as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 39.63% to $1.0 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $1.0 billion, a 39.63% increase, with the full-year FY2023 number at $197.3 million, down 68.15% from a year prior.
  • Accumulated Expenses was $1.0 billion for Q3 2025 at BeOne Medicines, up from $908.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.0 billion in Q3 2025 to a low of $197.3 million in Q4 2023.
  • A 5-year average of $602.6 million and a median of $588.8 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 74.05% in 2021, then plummeted 68.15% in 2023.
  • BeOne Medicines' Accumulated Expenses stood at $558.1 million in 2021, then increased by 11.01% to $619.5 million in 2022, then crashed by 68.15% to $197.3 million in 2023, then surged by 263.6% to $717.3 million in 2024, then surged by 39.63% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Accumulated Expenses are $1.0 billion (Q3 2025), $908.9 million (Q2 2025), and $717.3 million (Q3 2024).